![]() |
市場調査レポート
商品コード
1618259
大動脈瘤ステントグラフト:市場洞察・競合環境・市場予測 (~2030年)Aortic Aneurysm Stent Grafts - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
||||||
カスタマイズ可能
適宜更新あり
|
大動脈瘤ステントグラフト:市場洞察・競合環境・市場予測 (~2030年) |
出版日: 2024年12月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
大動脈瘤ステントグラフトの市場規模は、2024年から2030年までの予測期間中にCAGR 5.71%で成長すると予測されています。
大動脈瘤ステントグラフトの市場は、糖尿病を含む生活習慣病の有病率の増加、高齢者人口の増加、革新的な製品開発活動、低侵襲手技の採用の増加などにより、大幅な成長を示しています。
大動脈瘤ステントグラフト:市場力学
International Diabetes Federationのデータ (2022年) によると、20歳から79歳の成人5億3,700万人が糖尿病を患っており、これは約10人に1人に相当します。この数は2030年には6億4,300万人に増加し、2045年には7億8,300万人に達すると予想されています。注目すべきは、成人の糖尿病患者の75%以上が低・中所得国に居住していることです。さらに、5億4,100万人の成人が2型糖尿病の発症リスクが高い耐糖能障害を有しています。糖尿病に関連した高血圧、動脈硬化、肥満は動脈瘤のリスクを高めるため、この高リスク群における低侵襲動脈瘤管理のためにステントグラフトの使用を増やす必要があり、大動脈瘤ステントグラフトデバイスに対する需要が高まっています。
製品別では、腹部大動脈ステントグラフトの部門が2023年に大きな収益シェアを占めると予想されています。
腹部大動脈ステントグラフトは、腹部大動脈瘤の治療専用に設計された血管内デバイスであり、開腹手術をせずに動脈瘤の修復を容易にします。ステントフレームにはニチノールやステンレス鋼、織布にはポリエステルやポリテトラフルオロエチレンなど、生体適合性と耐久性に優れた素材が使用されています。これらの器具は構造的完全性を提供し、血管のリモデリングを促進します。主な特徴としては、自己拡張型またはバルーン拡張型のデザイン、移動を防止する高度なアンカー機構、腎動脈や腸骨動脈付近の複雑な動脈瘤を含む患者に対する柵状部や分岐部などがあります。
これらは、特に合併症を有する患者や開腹手術のリスクが高いと考えられる患者において、広く臨床的に採用されています。また、腹部大動脈ステントグラフトは動脈瘤関連の死亡率を減少させることに成功しており、器具のカスタマイズにおける継続的な開発に拍車がかかり、オーダーメイドの血管内ソリューションを通じて患者の転帰を改善しています。
地域別では、北米が2023年の市場を独占し、予測期間中も同様と見通しと予想されています。これは、糖尿病およびそれに関連するリスク要因の多さ、製品開発および規制当局の承認における著しい進歩、市場の主要企業の存在、確立された高度ヘルスケアインフラのアベイラビリティなど、いくつかの要因が寄与しています。
当レポートでは、世界の大動脈瘤ステントグラフトの市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。
Aortic Aneurysm Stent Grafts Devices Market by Product (Abdominal Aortic Stent Graft and Thoracic Aortic Stent Graft), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of lifestyle disorders and the rising product developmental activities worldwide
The aortic aneurysm stent grafts devices market is growing at a CAGR of 5.71% during the forecast period from 2024 to 2030. The aortic aneurysm stent grafts devices market is observing substantial market growth primarily owing to the increasing prevalence of lifestyle disorders including diabetes, the rising geriatric population, innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive procedures that are expected to escalate the overall growth of the aortic aneurysm stent grafts devices market during the forecast period from 2024 to 2030.
Aortic Aneurysm Stent Grafts Devices Market Dynamics:
According to data from the International Diabetes Federation (2022), in 2021, 537 million adults aged 20-79 were living with diabetes, equating to about 1 in 10 individuals. This number is expected to increase to 643 million by 2030 and reach 783 million by 2045. Notably, over 75% of adults with diabetes reside in low- and middle-income countries. Additionally, 541 million adults have impaired glucose tolerance, putting them at elevated risk for developing type 2 diabetes. Diabetes-related hypertension, atherosclerosis, and obesity elevate aneurysm risks, necessitating increased use of stent grafts for minimally invasive aneurysm management in this high-risk group, there is a growing demand for aortic aneurysm stent grafts devices.
Increased product developmental activities by the regulatory bodies worldwide are also slated to witness market growth for aortic aneurysm stent graft devices. For example, in June 2023, Cook Medical received FDA approval to initiate an investigational device exemption (IDE) study for an aortic aneurysm treatment. The study will evaluate the Zenith Fenestrated+ Endovascular Graft (ZFEN+).
Therefore, all the factors stated above collectively will drive the overall aortic aneurysm stent grafts devices market growth.
However, complications associated with aortic aneurysm stent grafts devices, and others may prove to be challenging factors for the aortic aneurysm stent grafts devices market growth.
Aortic Aneurysm Stent Grafts Devices Market Segment Analysis:
Aortic Aneurysm Stent Grafts Devices Market by Product (Abdominal Aortic Stent Graft and Thoracic Aortic Stent Graft), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of aortic aneurysm stent graft devices, the abdominal aortic stent graft category is expected to have a significant revenue share in the year 2023. This is because of the widespread uses and various key features of abdominal aortic stent grafts that enhance their utility and effectiveness.
Abdominal aortic stent grafts are endovascular devices designed specifically for the treatment of abdominal aortic aneurysms, facilitating aneurysm repair without open surgery. Constructed from biocompatible, durable materials like nitinol or stainless steel for the stent frame and woven polyester or polytetrafluoroethylene. These devices provide structural integrity and promote vascular remodeling. Key features include self-expanding or balloon-expandable designs, advanced anchoring mechanisms to prevent migration, and fenestrations or branches for cases involving complex aneurysms near renal or iliac arteries.
These have achieved widespread clinical adoption, particularly in cases where patients present with comorbidities or are considered at high-risk for open surgery. The success of abdominal aortic stent grafts in reducing aneurysm-related mortality also have spurred continued development in device customization, addressing variable aortic anatomies and improving patient outcomes through tailored endovascular solutions.
Additionally, in August 2024, Terumo India, announced the launch of the TREO Stent-Graft System, an advanced solution for Endovascular Aneurysm Repair (EVAR). Designed specifically for the treatment of infrarenal abdominal aortic aneurysms in adults with suitable anatomies, the TREO(R) Stent-Graft System stands out as the only EVAR graft featuring both suprarenal and infrarenal active fixation.
Therefore, the widespread uses and various key features of abdominal aortic stent graft that enhance performance and usability coupled with introduction of new and innovative products are solidifying the impact on the growth of the overall abdominal aortic stent graft devices market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall aortic aneurysm stent grafts devices market:
Among all the regions, North America is expected to dominate the aortic aneurysm stent grafts devices market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of diabetes, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure are acting as key factors contributing to the growth of the aortic aneurysm stent grafts devices market in the North America region during the forecast period from 2024 to 2030.
As per the recent data provided by the Centre for Disease Control and Prevention (2024), in 2021, 38.4 million people of all ages, or 11.6% of the US population had diabetes. The rising diabetic population is expanding demand for aortic aneurysm stent grafts, as diabetes heightens vascular complications, weakening the aortic wall. Diabetic patients' higher surgical risk makes minimally invasive stent grafts a preferred intervention, driving market growth in aneurysm management.
Product developmental activities initiated by regulatory bodies and key manufacturers will further boost the market for aortic aneurysm stent grafts devices. For example, in May 2021, Endologix LLC, a leader in the treatment of vascular disease, announced the first implant of its ALTO(R) Abdominal Stent Graft in Canada following recent approval from Health Canada.
Additionally, in August 2021, Terumo Aortic announced that the US Food and Drug Administration (FDA) granted approval of its RelayPro thoracic stent-graft system for sale in the USA for the treatment of patients with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAUs).
The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional aortic aneurysm stent grafts devices market growth. The presence of key players such as Cook, Medtronic, and Cordis, with their strong distribution networks, ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American aortic aneurysm stent grafts devices market.
Aortic Aneurysm Stent Grafts Devices Market key players:
Some of the key market players operating in the aortic aneurysm stent graft devices market include Medtronic, Terumo Corporation, Microport Scientific Corporation, Cook, Cordis, W. L. Gore & Associates, Inc., Endologix LLC, SB-KAWASUMI LABORATORIES, INC., Endospan, Lombard Medical, and others.
Recent Developmental Activities in the Aortic Aneurysm Stent Grafts Devices Market:
Key Takeaways from the Aortic Aneurysm Stent Grafts Devices Market Report Study
Target Audience who can be benefited from this Aortic Aneurysm Stent Grafts Devices Market Report Study
Frequently Asked Questions for the Aortic Aneurysm Stent Grafts Devices Market: